Commonwealth Equity Services LLC cut its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 7.1% in the 2nd quarter, Holdings Channel reports. The firm owned 23,868 shares of the company’s stock after selling 1,827 shares during the period. Commonwealth Equity Services LLC’s holdings in Takeda Pharmaceutical were worth $309,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Securities Inc. acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth $28,000. Wells Fargo & Company MN increased its holdings in Takeda Pharmaceutical by 1.7% in the fourth quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock valued at $11,053,000 after purchasing an additional 12,756 shares during the period. Aigen Investment Management LP acquired a new stake in Takeda Pharmaceutical during the 4th quarter worth about $197,000. Catalytic Wealth RIA LLC acquired a new stake in Takeda Pharmaceutical during the 4th quarter worth about $233,000. Finally, Gold Investment Management Ltd. acquired a new stake in Takeda Pharmaceutical during the 4th quarter worth about $994,000. 9.17% of the stock is currently owned by institutional investors.
Takeda Pharmaceutical Price Performance
TAK stock opened at $14.91 on Tuesday. The stock has a market capitalization of $47.19 billion, a PE ratio of 27.11, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. The company’s 50-day moving average is $14.35 and its 200-day moving average is $13.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $16.06.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
- Five stocks we like better than Takeda Pharmaceutical
- High Dividend REITs: Are They an Ideal Way to Diversify?
- The Average 401k Balance by Age Explained
- Best Stocks Under $5.00
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is a Special Dividend?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.